Intra-Cellular Therapies, Inc. (ITCI): Business Model Canvas [Apr-2026 Updated]

You're looking at Intra-Cellular Therapies, Inc. (ITCI) not as a small-cap biotech anymore, but as a high-growth unit inside Johnson & Johnson Innovative Medicine, which is a huge shift for its late-2025 business model. Honestly, the whole game now is about scaling CAPLYTA, which brought in $\mathbf{680.5 \text{ million}}$ in 2024 sales, aiming for that $\mathbf{0.7 \text{ billion}}$ incremental contribution to JNJ this year, all while funding the pipeline with $\mathbf{236.1 \text{ million}}$ in R&D. The core value-a unique drug with IP protection until 2040-is solid, but you need to see how they are managing the $\mathbf{504.5 \text{ million}}$ in 2024 selling costs and using that $\mathbf{1.0 \text{ billion}}$ cash reserve. Dive into the nine blocks below to see exactly how this new structure translates into revenue streams and key activities for the next decade.

Intra-Cellular Therapies, Inc. (ITCI) - Canvas Business Model: Key Partnerships

You're looking at the structure of Intra-Cellular Therapies, Inc. (ITCI) as of late 2025, which means we're talking about its integration into Johnson & Johnson (JNJ) Innovative Medicine, following the acquisition that closed on or around April 2, 2025.

The relationship with Johnson & Johnson (JNJ) Innovative Medicine is now the defining partnership, as JNJ acquired all outstanding shares of Intra-Cellular Therapies for $132.00 per share in cash, valuing the deal at approximately $14.6 billion.

This transaction was expected to contribute significantly to JNJ's 2025 performance, projecting an acceleration of sales growth by about 0.8%, translating to roughly $0.7 billion in incremental sales for the year.

Here's a quick look at how the key relationships shape the current commercial and legal landscape:

Partner Entity	Nature of Relationship	Key Financial/Date Metric
Johnson & Johnson (JNJ) Innovative Medicine	Parent Company/Acquirer	Acquisition closed April 2, 2025; $14.6 billion equity value.
Sandoz	Patent Settlement Partner	Generic CAPLYTA launch permitted on July 1, 2040, securing exclusivity until then.
Market Performance Context	Product Value Anchor	Full Year 2024 CAPLYTA net product sales were $680.5 million.
Market Potential Context	Future Revenue Driver	JNJ expects CAPLYTA to reach $5 billion in peak sales.

The Sandoz settlement was a major strategic win, locking in market exclusivity for CAPLYTA (lumateperone) until 2040, which is crucial since CAPLYTA is the sole marketed product.

The value underpinning these partnerships is CAPLYTA's commercial trajectory. Analysts projected the drug would likely achieve $1 billion-plus in sales in 2025, building on the 47% year-over-year growth seen in 2024.

The integration with JNJ immediately expanded the commercial reach and pipeline potential, which is evident in recent regulatory milestones:

• FDA accepted the supplemental New Drug Application (sNDA) for adjunctive treatment of Major Depressive Disorder (MDD) in Q4 2024.
• JNJ secured US FDA approval for CAPLYTA as an adjunctive treatment for MDD on November 6, 2025, marking the third indication.
• The acquisition included ITI-1284, a Phase 2 compound being studied for Generalized Anxiety Disorder (GAD) and Alzheimer's disease-related psychosis and agitation.
• Intra-Cellular Therapies had 955 total employees prior to the April 2025 close.

For the distribution side, the physical supply chain relies on third-party Contract Manufacturing Organizations (CMOs) for drug substance and finished product supply, a model that continues under JNJ's oversight.

Also, Academic and Clinical Research Organizations (CROs) remain key for executing ongoing clinical trials, supporting the pipeline development that JNJ acquired.

Finance: review Q3 2025 revenue contribution from CAPLYTA under JNJ consolidation by end of next week.

Intra-Cellular Therapies, Inc. (ITCI) - Canvas Business Model: Key Activities

Commercialization and Marketing of CAPLYTA: Driving prescription growth in CNS disorders.

Intra-Cellular Therapies, Inc. saw significant commercial momentum leading into 2025, driven by CAPLYTA (lumateperone).

Metric	Value/Amount	Period/Context
CAPLYTA Net Product Sales	$680.5 million	Full Year 2024
CAPLYTA Net Product Sales Growth	47%	Full Year 2024 vs. 2023
CAPLYTA Q4 2024 Net Product Sales	$199.2 million	Q4 2024
CAPLYTA Q4 2024 Sales Growth	51%	Q4 2024 vs. Q4 2023
CAPLYTA Total Prescriptions Growth	38%	Q3 2024 vs. Q3 2023
Projected 2025 CAPLYTA Sales	$1 billion-plus	Analyst Estimate
Peak CAPLYTA Sales Guidance	At least $5 billion	Company Guidance

The company commenced a field sales force expansion in the first quarter of 2025 in preparation for potential new indications.

Late-stage Clinical Development: Advancing lumateperone (CAPLYTA) for new indications like MDD.

The key activity here centers on the supplemental New Drug Application (sNDA) for Major Depressive Disorder (MDD) adjunctive therapy.

• sNDA submitted to the FDA in December 2024.
• MDD affects an estimated 21 million adults in the United States.
• Phase 3 Study 501 showed a 4.9-point reduction in MADRS total score versus placebo.
• Phase 3 Study 502 showed a 4.5-point reduction in MADRS total score versus placebo.
• FDA approval for adjunctive MDD was projected by analysts for the second half of 2025.

Research and Development (R&D): Focused on pipeline assets like ITI-1284 in Phase 2 studies.

R&D spending reflects the commitment to advancing the pipeline beyond the core asset.

Expense/Program	Value/Status	Period/Context
Research and Development (R&D) Expenses	$236.1 million	Full Year 2024
ITI-1284 Indication Status	Phase 2 ongoing	Generalized Anxiety Disorder (GAD), Alzheimer's Psychosis/Agitation
ITI-214 (Lenrispodun) Phase 2 Results	Anticipated in 2025	Parkinson's Disease (PD) motor symptoms
ITI-1020 Program Status	Phase 1 single ascending dose ongoing	Oncology indications

ITI-1284 is a deuterated form of lumateperone, and the FDA required additional toxicology studies as it does not consider the forms identical.

Regulatory Affairs Management: Securing FDA approval for the adjunctive MDD sNDA.

The successful acceptance of the MDD sNDA by the FDA was a critical regulatory milestone achieved in early 2025.

• FDA accepted the sNDA for lumateperone as adjunctive treatment for MDD.
• The company initiated a field sales force expansion in the first quarter of 2025 in anticipation of potential approval.

Intellectual Property (IP) Protection: Defending the core asset, lumateperone.

The ultimate validation of the core asset's value was the acquisition by Johnson & Johnson in January 2025.

Transaction Detail	Value/Amount	Date/Context
Acquisition Price Per Share	$132 in cash	Announced January 2025
Total Equity Value of Acquisition	About $14.6 billion	Announced January 2025
Acquisition Premium	40%	Compared to pre-deal trading

The acquisition secured the rights to lumateperone and brought in the clinical-stage agent ITI-1284 into the acquirer's portfolio.

Intra-Cellular Therapies, Inc. (ITCI) - Canvas Business Model: Key Resources

You're looking at the core assets that power Intra-Cellular Therapies, Inc. now that it's part of Johnson & Johnson Innovative Medicine. The value here is heavily concentrated in one successful drug and the future potential locked in its pipeline and patents. Honestly, the biggest resource event of 2025 was the acquisition itself, which fundamentally changed the financial backing.

CAPLYTA (lumateperone): The Sole Commercialized Product

CAPLYTA is the engine. Its commercial performance has been strong, driving significant year-over-year growth leading up to the acquisition. You need to see the trajectory of its revenue generation.

Full-year 2024 net product sales for CAPLYTA reached $680.5 million, a 47% increase compared to 2023. For the fourth quarter of 2024 specifically, net product sales were $199.2 million, marking a 51% increase over Q4 2023. Analysts projected CAPLYTA could generate $1 billion-plus in sales for 2025. Johnson & Johnson estimated peak annual sales for CAPLYTA to be $5 billion+.

Here's a snapshot of the recent sales performance:

Metric	Amount/Value	Period/Date
Full Year 2024 Net Product Sales	$680.5 million	Year Ended December 31, 2024
Q4 2024 Net Product Sales	$199.2 million	Q4 2024
Q3 2024 Net Product Sales	$175.2 million	Q3 2024
First Half 2024 Net Product Sales	$306.1 million	H1 2024
Projected 2025 Net Sales (Analyst Estimate)	$1 billion-plus	2025

Intellectual Property Portfolio

The patents are what secured the revenue stream for the near-to-mid-term future. The Sandoz settlement was key to establishing this timeline.

Intra-Cellular Therapies, Inc. has a portfolio that includes 27 US drug patents filed between 2020 and 2025, with 25 currently active. The settlement with Sandoz permits generic versions of CAPLYTA to launch starting July 1, 2040, effectively protecting market exclusivity until that date. Another estimate places the generic launch date at Dec 10, 2040.

Clinical Pipeline Assets

The pipeline, particularly ITI-1284, represents future value that Johnson & Johnson acquired. You're looking at assets targeting large patient populations.

The key pipeline assets include:

• ITI-1284-ODT-SL: A deuterated form of lumateperone in Phase 2 for Generalized Anxiety Disorder (GAD) and for psychosis/agitation associated with Alzheimer's disease.
• ITI-214 (Lenrispodun): A PDE1 inhibitor with Phase 2 clinical trial topline results anticipated in 2025 for Parkinson's disease.
• Lumateperone MDD sNDA: A supplemental New Drug Application was submitted for adjunctive treatment of Major Depressive Disorder (MDD).

For GAD, the Phase 2 benchmark for transitioning to Phase III is a 52% phase transition success rate. The trial for ITI-1284 in Alzheimer's psychosis (NCT06540833) started on Aug. 15, 2024, with a required reporting date of Sept. 29, 2028.

Expanded Commercial Sales Force

Scaling the field team was a direct action taken to maximize CAPLYTA's reach before the acquisition closed.

In the first quarter of 2025, the company executed a sales force expansion, adding approximately 150 sales representatives to target primary care physicians. A second expansion was planned for 2025, tied to the potential approval of CAPLYTA for MDD.

Financial Capital

The ultimate financial resource in 2025 was the acquisition itself, providing deep capital backing.

Johnson & Johnson acquired Intra-Cellular Therapies, Inc. for a total equity value of approximately $14.6 billion, paying $132.00 per share in cash. The transaction was completed on or around April 2, 2025. For Johnson & Johnson's 2025 outlook, the deal was expected to dilute adjusted earnings per share (EPS) by about $0.25. As of the end of 2024, Intra-Cellular Therapies, Inc. held $1.0 billion in cash, cash equivalents, investment securities, and restricted cash.

Intra-Cellular Therapies, Inc. (ITCI) - Canvas Business Model: Value Propositions

Intra-Cellular Therapies, Inc. (ITCI) offers CAPLYTA (lumateperone) as a differentiated treatment option in central nervous system (CNS) disorders, with value propositions centered on novel pharmacology, expanded indications, and patient convenience.

Novel Mechanism of Action: Differentiating CAPLYTA from older antipsychotics with a unique profile.

The efficacy of CAPLYTA is thought to be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. At therapeutic doses, CAPLYTA is characterized by high serotonin 5-HT2A receptor occupancy and lower amounts of dopamine D2 receptor occupancy. This profile supports its clinical differentiation.

Treatment for Bipolar Depression: First and only monotherapy/adjunctive treatment approved for bipolar I or II.

CAPLYTA 42 mg is the first and only U.S. Food and Drug Administration (FDA)-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) when used as monotherapy or as adjunctive therapy with lithium or valproate. Full year 2024 net product sales for CAPLYTA reached $680.5 million, representing a 47% year-over-year growth, with the bipolar depression indication contributing significantly to this trajectory.

Expanded Patient Population: Potential near-term approval for adjunctive Major Depressive Disorder (MDD).

Intra-Cellular Therapies, Inc. advanced its vision for CAPLYTA across mood disorders with the FDA approval of CAPLYTA as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults on November 6, 2025. This potential expansion is significant, as the Major Depressive Disorder market across the eight major markets is expected to reach $9.6 billion by 2029. Analyst expectations suggest CAPLYTA could achieve peak sales of at least $5 billion, driven primarily by bipolar depression and MDD. In anticipation of this potential approval, the company commenced a field sales force expansion in the first quarter of 2025.

Once-Daily Oral Dosing: Simple, convenient regimen for chronic CNS conditions.

CAPLYTA makes it easy for patients to start and stay on treatment because it does not require dose titration. The required regimen is an oral, once-daily dose.

Strong Efficacy and Tolerability: Offering a defintely needed balance for patients.

The value proposition is reinforced by clinical data showing robust efficacy alongside a favorable safety and tolerability profile, particularly regarding metabolic and weight effects, which are common reasons for treatment discontinuation with other agents. For schizophrenia relapse prevention, CAPLYTA treatment was associated with a 63% reduction in the risk of relapse compared to placebo in a Phase III trial.

Here's a look at the efficacy and tolerability data points:

Parameter	Indication/Study Context	Value/Finding
MADRS Total Score Separation vs. Placebo (Primary Endpoint)	MDD Adjunctive (Study 501 at 6 weeks)	4.9 points
MADRS Total Score Separation vs. Placebo (Primary Endpoint)	MDD Adjunctive (Study 502 at 6 weeks)	4.5 points
Remission Rate (MADRS Total score $\le$ 10)	MDD Adjunctive (6-month open-label safety study)	65%
Risk Reduction in Relapse	Schizophrenia (Phase III Study 304)	63% vs. placebo
Weight Change / Metabolic Effects	MDD Pivotal Trials (Pooled Safety Data)	Similar to placebo
Extrapyramidal Symptoms (EPS) Rates	MDD Pivotal Trials	Low

The safety profile in the MDD trials was consistent with existing data, and no new safety concerns were identified. The most commonly reported adverse events ($\ge$ 5% and $\ge$ twice placebo rate) in MDD trials included:

• dizziness
• dry mouth
• somnolence/sedation
• nausea
• fatigue
• diarrhea

In a long-term open-label safety study for MDD, 85% of patients stayed on CAPLYTA during the 6-month trial period.

Intra-Cellular Therapies, Inc. (ITCI) - Canvas Business Model: Customer Relationships

You're looking at how Intra-Cellular Therapies, Inc. (ITCI), now operating as a business unit within Johnson & Johnson Innovative Medicine following the April 2025 acquisition, structures its engagement with healthcare providers and patients for CAPLYTA (lumateperone).

Dedicated Sales Force: High-touch, educational engagement with CNS specialists

The customer relationship model relies heavily on a specialized sales force for high-touch engagement with Central Nervous System (CNS) specialists. This effort was scaled significantly to support the product's growth trajectory, which saw full year 2024 net product sales reach $680.5 million, a 47% increase over 2023.

The sales force size and reach metrics show a clear commitment to direct physician detailing:

Metric	Value	Context/Date
Sales Representatives (Pre-Expansion)	Approximately 530	Late 2024, before planned 2025 expansion.
Healthcare Providers Addressed (Pre-Expansion)	43,000	Before late 2024 expansion.
Sales Force Expansion (Q3 2024)	Approximately 150 representatives added	To leverage growing opportunity with primary care physicians.
Healthcare Providers Addressed (Post-Expansion)	Over 70,000	As of late 2024.

Expanding Primary Care Outreach

Intra-Cellular Therapies, Inc. actively broadened its prescriber base by targeting primary care physicians (PCPs), a strategy intensified in anticipation of the potential 2025 approval for adjunctive Major Depressive Disorder (MDD) treatment. This involved sequential sales force build-outs.

• A first expansion in the third quarter of 2024 added approximately 150 sales representatives.
• A second primary care physician sales force expansion was planned for 2025.
• The company commenced a field sales force expansion in the first quarter of 2025.

Selling, General and Administrative (SG&A) expenses reflected this investment, rising to $504.5 million for the full year ended December 31, 2024, compared to $409.9 million in 2023, primarily due to commercialization and marketing costs, including sales force expansion.

Patient Support Programs

To ensure access and affordability for patients prescribed CAPLYTA, the Intra-Cellular Therapies Patient Assistance Program (PAP) is in place, now managed under Johnson & Johnson. Eligibility for this program is tied to specific financial thresholds based on the 2025 federal poverty guidelines.

The program is available to eligible patients who meet income criteria, specifically having an income within 300% of the federal poverty level.

The 2025 Federal Poverty Guidelines for PAP eligibility include:

• Household of 1 person: Annual Income up to $46,950.
• Household of 4 people: Annual Income up to $96,450.
• Household of 6 people: Annual Income up to $129,450.
• For households over 6 people, an additional $16,110 is added per person.

Nationally, studies show that 28% of adults struggle to pay for prescription drugs, and of those, about 30% did not take them as prescribed due to cost sensitivities. The PAP is designed to mitigate this barrier for eligible patients.

Key Opinion Leader (KOL) Engagement

Building clinical advocacy through Key Opinion Leader (KOL) engagement is a critical component, translating scientific rationale into clinical adoption. While specific Intra-Cellular Therapies, Inc. KOL engagement metrics for late 2025 are not public, the commercial success implies effective advocacy. The focus for KOL engagement in 2025 across the industry is on omnichannel, tech-backed, and purposeful interactions to drive scientific exchange and market impact.

The successful submission of the supplemental New Drug Application (sNDA) for adjunctive MDD treatment in early 2025, following positive Phase 3 data, is a direct outcome of strong scientific communication, which KOLs help amplify. The potential for CAPLYTA to reach over $5 billion in peak year sales further underscores the importance of this relationship-building to solidify its position as a standard of care.

Intra-Cellular Therapies, Inc. (ITCI) - Canvas Business Model: Channels

You're looking at how Intra-Cellular Therapies, Inc. (ITCI) gets CAPLYTA (lumateperone) into the hands of prescribers and patients. This is all about the physical and promotional pathways they use to drive revenue, especially as they prepare for the potential Major Depressive Disorder (MDD) label expansion.

Direct Sales Force: Intra-Cellular Therapies, Inc. has been actively building out its commercial reach. In the third quarter of 2024, the company completed an expansion, adding approximately 150 sales representatives specifically to target primary care physicians for the existing bipolar depression indication. This followed an earlier build, bringing the total sales force to about 530 sales reps as of late 2024/early 2025. Furthermore, a second primary care physician sales force expansion is planned for 2025, contingent on the potential approval of CAPLYTA for adjunctive treatment of MDD. This team educates the prescriber base, which includes psychiatrists, nurse practitioners, and primary care physicians.

The reach of this direct effort is measurable by the prescriber base. As of the third quarter of 2024, the cumulative total of unique prescribers for CAPLYTA had increased to over 49,000 unique prescribers. This metric directly relates to the goal of expanding the team to target over 49,000 cumulative prescribers, as mentioned in your outline.

Channel Metric	Data Point	Date/Context
Sales Force Expansion (Q3 2024)	150 new sales representatives added	Q3 2024
Total Sales Force Size (Approximate)	About 530 sales reps	Late 2024/Early 2025
Planned Sales Force Expansion	A second expansion planned	For 2025, tied to potential MDD approval
Cumulative Unique Prescribers	Over 49,000	As of Q3 2024

Third-Party Wholesale Distributors: This represents the standard pharmaceutical supply chain for getting the physical product onto pharmacy shelves. While specific distributor contracts aren't public, the success of net product sales is the financial evidence of this channel working. Full-year 2024 net product sales for CAPLYTA reached $680.5 million. For the first quarter of 2025, reported sales were USD 21,893 million compared to USD 21,383 million a year ago, though this figure requires careful review against other reported quarterly sales figures. The gross-to-net percentage for the product has consistently been in the mid-30s.

Specialty Pharmacies: Access through specialty pharmacies is crucial for patient onboarding, especially for newer indications or complex patient populations. The company's commercial team focuses on educating the prescriber base, which includes psychiatrists, nurse practitioners, and primary care physicians. The growth in total prescriptions, which increased 38% year-over-year in Q3 2024, shows the effectiveness of the combined distribution and sales efforts in reaching patients.

Digital and Direct-to-Consumer (DTC) Advertising: Intra-Cellular Therapies, Inc. maintains a significant marketing presence to drive awareness among both physicians and patients. The company stated its conviction is to keep up with DTC and streaming advertising, noting their television ads appear alongside those for competitors like Vraylar and Rexulti. In the first quarter of 2024, they launched a new consumer TV advertisement specifically depicting the experience of people living with bipolar depression and the potential benefits of CAPLYTA. Selling, general and administrative (SG&A) expenses, which cover commercialization and marketing costs, were $504.5 million for the full year ended December 31, 2024.

Finance: review the Q1 2025 SG&A spend against the planned 2025 sales force expansion by end of month.

Intra-Cellular Therapies, Inc. (ITCI) - Canvas Business Model: Customer Segments

You're looking at the customer base for Intra-Cellular Therapies, Inc. (ITCI) right before the Johnson & Johnson acquisition closed in the second quarter of 2025. The focus is clearly on maximizing the penetration of CAPLYTA across existing and newly targeted patient populations.

Psychiatrists and CNS Specialists: Primary prescribers for schizophrenia and bipolar depression

These specialists represent the established core of the customer base. The growth in adoption here has been substantial. By the end of the third quarter of 2024, the cumulative number of unique prescribers for CAPLYTA had surpassed 49,000. This is a significant jump from the 36,000 psychiatrists prescribing the drug at the end of 2023. You see this translating directly into prescription volume; total prescriptions in Q3 2024 grew 38% year-over-year. Honestly, the depth of prescribing among existing users is as important as adding new ones, which is why the commercial team was focused on optimizing that base.

Primary Care Physicians (PCPs): Growing target segment for bipolar depression and potential MDD

Recognizing the sheer volume of patients managed outside of specialty care, Intra-Cellular Therapies, Inc. made a clear strategic pivot to PCPs. To support this, the company completed an expansion of its sales force in the third quarter of 2024, adding 150 new sales representatives specifically to leverage the growing opportunity within the PCP segment for bipolar depression. This move signals a belief that CAPLYTA's profile supports broader use beyond the CNS specialist setting, especially as the company anticipated potential MDD label expansion.

Adult Patients: Diagnosed with schizophrenia or depressive episodes of bipolar disorder

The patient segment is defined by the approved indications for CAPLYTA. For schizophrenia, the drug was first approved in 2019. The label expanded in 2021 to include depressive episodes associated with bipolar I or II disorder. The market opportunity for the potential MDD indication is massive; approximately 21 million adults in the United States suffer from Major Depressive Disorder each year. If the supplemental New Drug Application (sNDA) for MDD, submitted in December 2024, had been approved by late 2025, the addressable patient pool would have grown considerably, with analysts projecting peak annual sales potential exceeding $3 billion from that expansion alone. The drug is available in 10.5 mg, 21 mg, and 42 mg capsules.

Here's a quick look at the market penetration and financial scale leading into 2025:

Metric	Value/Amount	Period/Context
Full Year 2024 Net Product Sales	$680.5 million	Full Year 2024
Q3 2024 Net Product Sales	$175.2 million	Q3 2024
Q3 2024 YoY Net Sales Growth	39%	Q3 2024 vs. Q3 2023
Cumulative Unique Prescribers	Over 49,000	As of Q3 2024
Estimated US MDD Population	21 million adults	Annual Prevalence
JNJ Acquisition Equity Value	Approx. $14.6 billion	January 2025 Announcement

Payers and Pharmacy Benefit Managers (PBMs): Negotiating formulary access and reimbursement

Securing favorable formulary placement with Payers and PBMs is non-negotiable for driving prescription volume. The gross-to-net percentage for CAPLYTA remained in the mid-30s for Q3 2024, indicating the level of rebates and discounts necessary to achieve net sales from gross sales. The acquisition by Johnson & Johnson in early 2025 for $132.00 per share suggests a high valuation placed on the drug's existing revenue stream and future formulary leverage, especially with the anticipated MDD approval. JNJ expected the deal to contribute approximately $0.7B in incremental sales to its 2025 figures. This transition means that formulary negotiations and contracting strategy are now integrated into the larger JNJ Innovative Medicine business unit, which has a deep history in neuroscience.

The company's financial position remained strong, with cash and investments totaling $1 billion as of September 30, 2024, which provided the necessary capital to execute the sales force expansion targeting PCPs before the acquisition closed. The patent settlement with Sandoz, postponing generic competition until 2040, was a major factor strengthening the perceived value to JNJ and securing the long-term revenue stream from these customer segments.

• Securing preferred access for schizophrenia and bipolar depression.
• Driving utilization through favorable tier placement.
• Anticipating streamlined PBM negotiations post-JNJ integration.
• Gross-to-Net realization was in the mid-30s range in Q3 2024.

Finance: draft Q4 2025 pro-forma cash flow analysis incorporating JNJ synergy estimates by Friday.

Intra-Cellular Therapies, Inc. (ITCI) - Canvas Business Model: Cost Structure

You're looking at the major drains on Intra-Cellular Therapies, Inc.'s cash flow as they scale CAPLYTA and advance their pipeline. For a company in this phase, the cost structure is heavily weighted toward commercial execution and pipeline development. Honestly, these are the costs you expect when you have a successful launch and big pipeline ambitions.

The primary cost drivers fall into three main buckets based on the full-year 2024 reported figures. You can see the scale of investment right away.

Cost Category	Full Year 2024 Amount (USD Millions)	Comparison/Context
Selling, General, and Administrative (SG&A) Expenses	$504.5 million	Up from $409.9 million in 2023; driven by commercialization, marketing, and infrastructure costs.
Research and Development (R&D) Expenses	$236.1 million	Up from $180.1 million in 2023; reflects higher project costs for lumateperone and non-lumateperone programs.
Cost of Goods Sold (COGS) / Cost of Revenue	$56.963 million	Represents manufacturing and supply chain costs for product sales in 2024.

The 2024 SG&A spend of $504.5 million clearly signals the high cost of building out a commercial presence for CAPLYTA. This is the price of market penetration.

The R&D spend was substantial, totaling $236.1 million for the year ended December 31, 2024. This investment is fueling the advancement of their entire portfolio.

• R&D increase primarily due to higher costs for lumateperone programs.
• R&D included costs for ITI-1284, ITI-214, and ITI-1500 programs.
• The company initiated 10 late-stage clinical trials in 2024.

For context on near-term spending, the company's 2024 guidance, reiterated earlier in the year, projected SG&A between $490 million and $510 million and R&D between $220 million and $230 million, showing a clear commitment to these high expense levels continuing into the period leading up to the Johnson & Johnson acquisition close in April 2025.

Regarding the sales force, you know they were actively investing in personnel to support CAPLYTA's growth. Intra-Cellular Therapies completed one expansion in Q3 2024, adding about 150 sales representatives to target primary care physicians. The planned investment for 2025 is directly tied to the potential approval of CAPLYTA for adjunctive treatment of Major Depressive Disorder (MDD).

Sales Force Expansion Costs: Investment in adding new primary care representatives in 2025.

• A second primary care physician sales force expansion was planned for 2025.
• This expansion was contingent on the potential approval of CAPLYTA for adjunctive MDD.
• The company commenced a field sales force expansion in the first quarter of 2025 in anticipation of potential approval.

What this estimate hides is the exact incremental cost of the 2025 expansion, as that specific figure wasn't broken out in the latest public filings available before the acquisition closed. Finance: draft 13-week cash view by Friday.

Intra-Cellular Therapies, Inc. (ITCI) - Canvas Business Model: Revenue Streams

You're looking at the revenue structure for Intra-Cellular Therapies, Inc. (ITCI) as it existed leading up to and following its acquisition by Johnson & Johnson (JNJ) in early 2025. Post-acquisition, these streams are now integrated into JNJ's financial reporting, but the underlying drivers are clear.

The primary engine for revenue was the commercial success of CAPLYTA (lumateperone). This product drove significant top-line growth, which ultimately made the company an attractive acquisition target.

Here's a quick look at the key figures driving the revenue picture:

Revenue Component	Financial Metric/Period	Amount
Net Product Sales of CAPLYTA	Full Year 2024	$680.5 million
Incremental Sales Contribution to JNJ	Expected 2025 Contribution	Approximately $0.7 billion
Investment Income Base	Cash Reserves as of December 31, 2024	$1.0 billion

The expected incremental sales contribution to JNJ in 2025, approximately $0.7 billion, reflects the projected performance of CAPLYTA following the transaction closing around April 2, 2025. This figure was part of JNJ's updated 2025 financial outlook.

For the future, the potential for milestone payments and royalties stems from the pipeline assets that were part of the acquisition. While these are now folded into JNJ's structure, the potential revenue streams were based on:

• ITI-1284 compound in development for Generalized Anxiety Disorder and Psychosis associated with Alzheimer's disease.
• Other non-lumateperone project costs, including ITI-214 and ITI-1500 programs mentioned in 2024 R&D updates.

Investment income represents a secondary, non-operating revenue source. The company maintained a substantial balance sheet position to support operations and development, evidenced by cash, cash equivalents, investment securities, and restricted cash totaling $1.0 billion at the close of 2024. That's a solid base for generating interest income, though it's dwarfed by product sales.